INTRODUCTION
In clinical trials of patients with type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have been shown to provide effective glycemic control when used in combination with oral antidiabetic drugs (OADs) [1] . However, data regarding the use of GLP-1 receptor agonists in clinical practice are scarce.
Here, the authors report data from the use of the once-daily human GLP-1 analog liraglutide in clinical practice.
Liraglutide is a once-daily human GLP-1 analog with 97% amino acid sequence identity to native GLP-1 [2] . In phase 3 trials, liraglutide has been found to provide glycemic control alongside potential beneficial effects on body weight, reductions in systolic blood pressure (SBP), and improved beta-cell function [3] [4] [5] [6] [7] [8] [9] . Liraglutide treatment has also been found to be associated with a low risk of hypoglycemia, particularly when used without concomitant sulfonylurea treatment [3] [4] [5] [6] [7] [8] [9] 
RESULTS

Patient Demographics and Baseline Characteristics
A total of 193 patients were included in the audit, 50 of whom (25.9%) were prescribed liraglutide off-license with existing insulin regimens (off-license use of liraglutide was initiated on investigator request and it was their sole responsibility). Among patients taking insulin in combination with liraglutide, 13 used basal insulin at baseline, 27 used basalbolus regimens, and 10 used a premixed insulin.
A total of 129 (66.8%) patients were male. The mean (SD) patient age was 55.8 (9.7) years, and mean (SD) duration of diabetes was 8. 
DISCUSSION
The changes observed here are comparable to those in phase 3 trials of liraglutide 1.2 mg in combination with OADs, in which HbA 1c decreases ranged from 1.0 to 1.5%, weight change from ?0.3 to -2.9 kg, and SBP decreases from 0.6 to 6.7 mmHg following 26-week treatment [3, 4, 6, 9] . At 5.7%, the occurrence of minor hypoglycemia in this study OADs [3, 4, 6, 9] . Limitations of the present study include its single-arm observational design, the absence of a fixed timeline for the first visit, and the fact that it was conducted at a single center. Furthermore, patients received concomitant medications that may have affected the measured outcomes, and these medications may have changed during the course of the study.
In this study, the insulin dose did not need to be reduced in patients who were using liraglutide with insulin. This observation is likely to be a reflection of the fact that initial glycemic control in these patients was poor. A clinical trial of the GLP-1 receptor agonist exenatide twice daily in combination with insulin also showed reductions in HbA 1c [12] , and another trial exploring the sequential addition to metformin of liraglutide and then insulin detemir also reported good glycemic control, sustained weight loss, and low rates of hypoglycemia [13] . Based on these data, in
Europe, exenatide twice daily is licensed for use in combination with basal insulin, and insulin detemir can be added to existing liraglutide therapy [14, 15] 
